Presentations and Publications • NGM Biopharmaceuticals

PRESENTATIONS & PUBLICATIONS

Topline Results from the ALPINE 2/3 Study: a Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2b Trial Evaluating 3 Doses of the FGF19 Analogue Aldafermin on Liver Histology in Patients with Nonalcoholic Steatohepatitis and Stage 2 and 3 Fibrosis

AASLD The Liver Meeting, Presidential Plenary Session, November 14, 2021

Listen to oral presentation
Download PDF of presentation

Inhibition of Complement C3 in Geographic Atrophy with NGM621: Phase 1 Dose-Escalation Study Results

American Journal of Ophthalmology, 2021

Initial results of a phase 1a/1b study of NGM120, a first-in-class anti-GDNF family receptor alpha like (GFRAL) antibody in patients with advanced solid tumors

ESMO Virtual Congress; September 16-21, 2021

The Fibronectin-ILT3 Interaction Functions as a Stromal Checkpoint that Suppresses Myeloid Cells

Cancer Immunology Research, 2021

Aldafermin Reduces Hydrophobic Bile Acids in a 24-Week Randomized, Double-Blind, Placebo-Controlled, Multicenter Study in Patients with Nonalcoholic Steatohepatitis

EASL 2021 International Liver Congress; June 23-26

Download PDF of poster
Download PDF of poster presentation
Listen to poster presentation

The Liver Fibroinflammatory Marker cT1 is Reduced with Aldafermin Therapy in a Randomized, Double-Blind, Placebo-Controlled, Multicenter Study in Patients with Nonalcoholic Steatohepatitis

EASL 2021 International Liver Congress; June 23-26

Download PDF of poster
Download PDF of poster presentation
Listen to poster presentation

The FGF19 Analogue Aldafermin Enriches the Lactate-Consuming, Bile Acid-Sensitive Commensal Microbe Veillonella in Patients with Primary Sclerosing Cholangitis

EASL 2021 International Liver Congress; June 23-26

Download PDF of poster
Download PDF of poster presentation
Listen to poster presentation

Atherosclerotic Cardiovascular Risk Assessment in a 24-Week, Randomized, Double-Blind Placebo-Controlled Study of Aldafermin

EASL 2021 International Liver Congress; June 23-26

Download PDF of poster
Download PDF of poster presentation
Listen to poster presentation

Potent Suppression of Hydrophobic Bile Acids by Aldafermin, an FGF19 Analogue, Across Metabolic and Cholestatic Liver Diseases

JHEP Reports, 2021

Inhibition of Complement C3 in Geographic Atrophy with NGM621: Phase 1 Study Results

Angiogenesis, Exudation, and Degeneration 2021 - Virtual Edition

Download PDF of presentation

Aldafermin (NGM282) produces greater anti-fibrotic response in patients with nonalcoholic steatohepatitis and advanced fibrosis

Late-breaker oral presentation, AASLD The Liver Meeting Digital Experience, November 15, 2020

Listen to late-breaker presentation
Download PDF of presentation

Final analysis of a 24-week, randomized, double-blind, placebo-controlled, multicenter study of aldafermin (NGM282) in patients with nonalcoholic steatohepatitis

AASLD The Liver Meeting Digital Experience, November 15, 2020

Watch narrated presentation
Download PDF of presentation

Lipid Management in a 24-week, randomized, double-blind, placebo-controlled study of aldafermin (NGM282)

AASLD The Liver Meeting Digital Experience, November 13, 2020

Listen to poster presentation
Download PDF of poster

Aldafermin (NGM282) improves APRI, FIB-4 and other non-invasive measures in patients with nonalcoholic steatohepatitis

AASLD The Liver Meeting Digital Experience, November 13, 2020

Listen to poster presentation
Download PDF of poster

Inhibition of Complement C3 in Geographic Atrophy with NGM621: Phase 1 Dose-Escalation Study Results

American Academy of Ophthalmology Meeting, November 2020

Watch narrated presentation
Download PDF of presentation

Positive topline results from a 24-week, placebo-controlled, multicenter, paired liver biopsy study of the FGF19 analogue aldafermin (NGM282) in patients with nonalcoholic steatohepatitis

Late-breaker oral plenary presentation, EASL Digital International Liver Congress; August 29, 2020

Watch narrated presentation
Download PDF of presentation

Aldafermin (NGM282) reduces the cross-linked pro-peptides of type III collagen PRO-C3X, a novel biomarker, in nonalcoholic steatohepatitis and primary sclerosing cholangitis patients

EASL Digital International Liver Congress; August 28, 2020

Listen to poster presentation
Download PDF of poster

Correlation of serum bile acids and pruritus with aldafermin (NGM282) therapy in patients with primary sclerosing cholangitis

EASL Digital International Liver Congress; August 28, 2020

Listen to poster presentation
Download PDF of poster

The FGF19 analogue aldafermin (NGM282) improves non-invasive tests in patients with nonalcoholic steatohepatitis

EASL Digital International Liver Congress; August 28, 2020

Listen to poster presentation
Download PDF of presentation

Veillonella as a bile acid-sensitive bacteria and a microbiome-based biomarker for aldafermin (NGM282) in patients with non-alcoholic steatohepatitis

EASL Digital International Liver Congress; August 27, 2020

Listen to poster presentation
Download poster PDF

The Commensal Microbe Veillonella as a Marker for Response to an FGF19 Analog in Nonalcoholic Steatohepatitis

Hepatology, 2021

Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis

Gastroenterology, 2020

NGM621 is a Potent Inhibitory anti-Complement C3 Antibody in Development for Treatment of Geographic Atrophy

The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting (virtual), June 2020

Watch narrated presentation
Download PDF of presentation
ARVO Annual Meeting Abstract

Efficacy of Complement C3 Inhibition in Preclinical Models of Wet Age-related Macular Degeneration (AMD)

The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting (virtual), June 2020

Watch narrated presentation
Download PDF of presentation
ARVO Annual Meeting Abstract

Stable Gut Microbiome Composition and Diversity with NGM282 (Aldafermin) Therapy in Patients with Non-Alcoholic Steatohepatitis

AASLD The Liver Meeting, Boston; November 11, 2019

NGM282 (Aldafermin), an FGF19 Analogue, Reduces Net Deposition of Collagen III in Non-Alcoholic Steatohepatitis and Primary Sclerosing Cholangitis

AASLD The Liver Meeting, Boston; November 11, 2019

12 Weeks of NGM282 (Aldafermin) Therapy Produced Significant and Sustained Reduction in cT1 in Patients with Non-Alcoholic Steatohepatitis

AASLD The Liver Meeting, Boston; November 11, 2019

Bile Acids and Liver Fibrosis: Shared Anti-Fibrotic Effects of NGM282 (Aldafermin), an FGF19 Analogue, in Primary Sclerosing Cholangitis and Non-Alcoholic Steatohepatitis

AASLD The Liver Meeting, Boston; November 9, 2019

NGM313, a novel activator of β-klotho/FGFR1c, improves insulin resistance and reduces hepatic fat in obese, non‐diabetic subjects

79th Scientific Sessions of the American Diabetes Association, San Francisco; June 8, 2019

NGM313, a Novel Activator of β-Klotho/FGFR1c: A Single Dose Significantly Reduces Steatosis (Liver Fat by MRI-PDFF), Inflammation (ALT, AST) and Fibrogenic Activity (Pro-C3) in NAFLD Subjects

EASL International Liver Congress, Vienna, Austria; April 12, 2019

Changes in Serum Bile Acids Correlate with 7alpha‐Hydroxy‐4‐Cholesten‐3‐One and Fibrogenesis Biomarker Pro‐C3 with NGM282 Therapy in Patients with Nonalcoholic Steatohepatitis

EASL International Liver Congress, Vienna, Austria; April 11-13, 2019

Serum Bile Acids Significantly Associate with the Fibrogenesis Biomarker Pro‐C3: Analysis of a Randomized, Placebo‐Controlled Trial of NGM282 in Patients with Primary Sclerosing Cholangitis (PSC)

EASL International Liver Congress, Vienna, Austria; April 11-13, 2019

Effect of NGM282, an FGF19 Analogue, on Pruritus in Patients with Primary Sclerosing Cholangitis: Analysis of a Phase 2, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial

EASL International Liver Congress, Vienna, Austria; April 11-13, 2019

NGM282 Promotes HDL Biogenesis and Transhepatic Cholesterol Efflux to Prevent Atherosclerosis in Mice

EASL International Liver Congress, Vienna, Austria; April 11-13, 2019

FGF19 Analogue as a Surgical Factor Mimetic that Contributes to Metabolic Effects Beyond Glucose Homeostasis

Diabetes, 2019

Therapeutic FGF19 Promotes HDL Biogenesis and Transhepatic Cholesterol Efflux to Prevent Atherosclerosis

Journal of Lipid Research, 2019

NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients with Nonalcoholic Steatohepatitis

Hepatology, 2019

Rosuvastatin Improves the FGF19 Analogue NGM282-Associated Lipid Changes in Patients with Non-Alcoholic Steatohepatitis

Journal of Hepatology, 2018

NGM282 Maintains a Durable Off-Treatment Response on Hepatic Steatosis, Inflammation and Fibrogenesis in Patients with Biopsy-Confirmed Nonalcoholic Steatohepatitis: Results of a Multi-Center Phase 2 Dose-Finding Study

AASLD The Liver Meeting, San Francisco; November 12, 2018

Effect of NGM282, an FGF19 Analogue, in Primary Sclerosing Cholangitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Trial

Journal of Hepatology, 2018

NGM282 Rapidly Improves NAFLD Activity Score (NAS) and Fibrosis in 12 Weeks in Patients with Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH): Results of a Phase 2 Multi-Center Dose Finding Study

AASLD The Liver Meeting, San Francisco; November 12, 2018

Fibrosis Regression Observed in Treatment with FGF19 Variants in a Diet Induced Mouse Model of Nonalcoholic Steatohepatitis (NASH) Is Predominantly Mediated By FGFR4 Activity and Independent of Weight Loss or Decreases in Hepatic Steatosis

AASLD The Liver Meeting, San Francisco; November 10, 2018

NGM282 Demonstrates Antinflammatory and Antifibrotic Activities That Are Independent of Steatosis Reduction in a Farnesiod X Receptor (FXR)-Deficient, Diet-Induced Animal Model of Nonalcoholic Steatohepatitis (NASH)

AASLD The Liver Meeting, San Francisco; November 10, 2018

Effects of NGM282, an FGF19 Variant, on Colonic Transit and Bowel Function in Functional Constipation: a Randomized Phase 2 Trial

The American Journal of Gastroenterology, 2018

NGM282 for Treatment of Non-Alcoholic Steatohepatitis: a Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial

The Lancet, 2018

Modulation of the Intestinal Bile Acid/Farnesoid X Receptor/Fibroblast Growth Factor 15 Axis Improves Alcoholic Liver Disease in Mice

Hepatology, 2018

NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Hepatology Communications, 2018

Dysregulation of Serum Bile Acids and FGF19 in Alcoholic Hepatitis

Journal of Hepatology, 2018

Mice Species-Specific Control of Hepatocarcinogenesis and Metabolism by FGF19/FGF15

Journal of Hepatology, 2017

Non-Cell-Autonomous Activation of IL-6/STAT3 Signaling Mediates FGF19-Driven Hepatocarcinogenesis

Nature Communications, 2017

Engineered FGF19 Eliminates Bile Acid Toxicity and Lipotoxicity Leading to Resolution of Steatohepatitis and Fibrosis in Mice

Hepatology Communications, 2017

Engineered Fibroblast Growth Factor 19 Reduces Liver Injury and Resolves Sclerosing Cholangitis in Mdr2-Deficient Mice

Hepatology, 2016

A nontumorigenic Variant of FGF19 Treats Cholestatic Liver Diseases

Science Translational Medicine, 2014

Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19

Cancer Research, 2014

NGM313, a Novel Once-Monthly Activator of β-Klotho/FGFR1c, Significantly Reduces Hepatic Steatosis and Key Biomarkers of Nonalcoholic Steatohepatitis: Results of a Randomized, Active-Controlled Clamp Study in Obese Insulin Resistant Patients with NAFLD

AASLD The Liver Meeting, San Francisco; November 12, 2018

Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15

Nature, 2017

LEAP2 Is an Endogenous Antagonist of the Ghrelin Receptor

Cell Metabolism, 2017

Apelin-36 Modulates Blood Glucose and Body Weight Independently of Canonical APJ Receptor Signaling

Journal of Biological Chemistry, 2016

Restoration of euglycemia after duodenal bypass surgery is reliant on central and peripheral inputs in Zucker fa/fa rats

Diabetes Journals, 2013

NGM282 Improves Fibrosis and NASH-Related Histology in 12 Weeks in Patients With Biopsy-Confirmed NASH, Which is Preceded By Significant Decreases in Hepatic Steatosis, Liver Transaminases and Fibrosis Markers at 6 Weeks

EASL International Liver Congress, Paris, France; April 14, 2018

"I think it takes a certain energy to be here because there is a lot of energy here. You have to be willing to expend that energy and hustle and get things done and move at the pace that the company moves. It’s not for everyone, but I think that’s very exciting."

MK

Biology

Career Opportunities

Top